MX2020005575A - Composiciones y metodos de taxano oral de alta resistencia. - Google Patents

Composiciones y metodos de taxano oral de alta resistencia.

Info

Publication number
MX2020005575A
MX2020005575A MX2020005575A MX2020005575A MX2020005575A MX 2020005575 A MX2020005575 A MX 2020005575A MX 2020005575 A MX2020005575 A MX 2020005575A MX 2020005575 A MX2020005575 A MX 2020005575A MX 2020005575 A MX2020005575 A MX 2020005575A
Authority
MX
Mexico
Prior art keywords
methods
oral
compositions
oral taxane
taxane compositions
Prior art date
Application number
MX2020005575A
Other languages
English (en)
Inventor
Ming Tsung Lee
Weng Li Yoon
Johnson Yiu- Nam LAU
Denise So Bik Chan
Jiahao Li
Original Assignee
Athenex Hk Innovative Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Hk Innovative Ltd filed Critical Athenex Hk Innovative Ltd
Publication of MX2020005575A publication Critical patent/MX2020005575A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El tema de la invención proporciona composiciones y métodos para producir dosis altas, composiciones de taxano oral de alta biodisponibilidad. Los taxanos orales se preparan como una dispersión sólida amorfa y se pueden proporcionar en forma de tabletas comprimidas. Sorprendentemente, la biodisponibilidad oral de los taxanos preparados y proporcionados en este tema es alta, incluso en ausencia de tensioactivos.
MX2020005575A 2017-10-06 2018-10-05 Composiciones y metodos de taxano oral de alta resistencia. MX2020005575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762569258P 2017-10-06 2017-10-06
PCT/US2018/054552 WO2019071092A1 (en) 2017-10-06 2018-10-05 ORAL TAXANE COMPOSITIONS OF HIGH POWER AND METHODS

Publications (1)

Publication Number Publication Date
MX2020005575A true MX2020005575A (es) 2021-04-28

Family

ID=65992356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005575A MX2020005575A (es) 2017-10-06 2018-10-05 Composiciones y metodos de taxano oral de alta resistencia.

Country Status (13)

Country Link
US (2) US20190105397A1 (es)
EP (1) EP3691612B1 (es)
JP (2) JP7597984B2 (es)
KR (2) KR20250048138A (es)
CN (1) CN111741744A (es)
AU (1) AU2018346616B2 (es)
BR (1) BR112020006893A2 (es)
CA (1) CA3078615A1 (es)
IL (1) IL273754B2 (es)
MX (1) MX2020005575A (es)
SG (1) SG11202003003TA (es)
TW (2) TWI833710B (es)
WO (1) WO2019071092A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI833710B (zh) * 2017-10-06 2024-03-01 香港商慧源香港創新有限公司 高單位含量口服型紫杉烷組合物及方法
WO2019221215A1 (ja) * 2018-05-18 2019-11-21 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物
TWI900672B (zh) 2020-10-07 2025-10-11 香港商希華醫藥有限公司 乙醯胺基－苯基四唑衍生物及其使用方法
CA3203543A1 (en) * 2020-12-30 2022-07-07 Rhythm Mehra Additively manufactured cable gland
CA3212644A1 (en) * 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2025128987A1 (en) * 2023-12-15 2025-06-19 Board Of Regents, The University Of Texas System Electromagnetic drop-on-demand (dod) technology as an innovative platform for amorphous solid dispersion production
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MX2010002179A (es) 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
CN103083240B (zh) * 2011-10-28 2015-12-09 沈阳药科大学 紫杉醇及其同系物的固体分散体及其口服制剂的制备
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
WO2014126969A1 (en) 2013-02-12 2014-08-21 Bend Research, Inc. Solid dispersions of low-water solubility actives
US9737538B2 (en) * 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN107028931A (zh) * 2016-02-04 2017-08-11 上海宣泰医药科技有限公司 一种紫杉醇药物组合物及其药物制剂、制备方法和用途
TWI833710B (zh) * 2017-10-06 2024-03-01 香港商慧源香港創新有限公司 高單位含量口服型紫杉烷組合物及方法

Also Published As

Publication number Publication date
EP3691612B1 (en) 2025-11-26
IL273754B2 (en) 2025-05-01
EP3691612C0 (en) 2025-11-26
TW201914580A (zh) 2019-04-16
NZ763143A (en) 2024-04-26
KR20200105811A (ko) 2020-09-09
BR112020006893A2 (pt) 2020-10-06
EP3691612A1 (en) 2020-08-12
TWI833710B (zh) 2024-03-01
WO2019071092A1 (en) 2019-04-11
SG11202003003TA (en) 2020-04-29
IL273754A (en) 2020-05-31
AU2018346616B2 (en) 2024-08-08
CA3078615A1 (en) 2019-04-11
JP7597984B2 (ja) 2024-12-11
EP3691612A4 (en) 2021-07-14
US20190105397A1 (en) 2019-04-11
JP7813969B2 (ja) 2026-02-16
AU2018346616A1 (en) 2020-04-23
JP2020536880A (ja) 2020-12-17
IL273754B1 (en) 2025-01-01
CN111741744A (zh) 2020-10-02
US20230321246A1 (en) 2023-10-12
KR20250048138A (ko) 2025-04-07
KR102789063B1 (ko) 2025-03-28
TW202435853A (zh) 2024-09-16
JP2024012683A (ja) 2024-01-30

Similar Documents

Publication Publication Date Title
MX2020005575A (es) Composiciones y metodos de taxano oral de alta resistencia.
EP4268892A3 (en) Matrix bound nanovesicles and their use
NZ712350A (en) Abiraterone acetate formulation
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
SG10201805024YA (en) Methods useful in the synthesis of halichondrin b analogs
AU2013293116A8 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
MX377729B (es) Métodos para tratamiento del melanoma.
WO2016007617A3 (en) Pharmaceutical compounding kit
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
IN2014MU00303A (es)
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
PH12016501841A1 (en) Immunosuppressant formulation
NZ731398A (en) Noscapinoid-producing microbes and methods of making and using the same
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
NZ723631A (en) Nanosuspension of natural materials and preparation method thereof
EP3581205A3 (en) Product and method for treating diarrhea
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
IN2014MU00916A (es)
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
AU2015317086B2 (en) Dry process for preparing a surface-modified alkaline earth metal carbonate-containing material
GEAP201914292A (en) Pharmaceutical formulations of vildagliptin